Research Article
Formulation and Optimization of Eudragit RS PO-Tenofovir Nanocarriers Using Box-Behnken Experimental Design
Table 3
Observed responses in BBD for Eudragit RS PO nanoparticles.
| | Formulation code | Variable levels in coded form | Dependent variables | | | | PS
(nm ± SD) | PDI
(±SD) | ZP
(mv ± SD) | EE (%) |
| | 1 | | | 0 | | | | 98 | | 2 | | | 0 | | | | 99 | | 3 | | | 0 | | | | 99 | | 4 | | | 0 | | | | 99 | | 5 | | 0 | | | | | 99 | | 6 | | 0 | | | | | 99 | | 7 | | 0 | | | | | 99 | | 8 | | 0 | | | | | 99 | | 9 | 0 | | | | | | 99 | | 10 | 0 | | | | | | 99 | | 11 | 0 | | | | | | 99 | | 12 | 0 | | | | | | 99 | | 13 | 0 | 0 | 0 | | | | 99 | | 14 | 0 | 0 | 0 | | | | 99 | | 15 | 0 | 0 | 0 | | | | 99 |
|
|
